547 related articles for article (PubMed ID: 25609661)
1. Dapagliflozin: A Sodium Glucose Cotransporter 2 Inhibitor for the Treatment of Diabetes Mellitus.
Davis PN; Ndefo UA; Oliver A
J Pharm Pract; 2016 Apr; 29(2):165-71. PubMed ID: 25609661
[TBL] [Abstract][Full Text] [Related]
2. Dapagliflozin: a new sodium-glucose cotransporter 2 inhibitor for treatment of type 2 diabetes.
Vivian EM
Am J Health Syst Pharm; 2015 Mar; 72(5):361-72. PubMed ID: 25694411
[TBL] [Abstract][Full Text] [Related]
3. Dapagliflozin for the treatment of type 2 diabetes.
Anderson SL; Marrs JC
Ann Pharmacother; 2012 Apr; 46(4):590-8. PubMed ID: 22433611
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus.
Fioretto P; Giaccari A; Sesti G
Cardiovasc Diabetol; 2015 Oct; 14():142. PubMed ID: 26474563
[TBL] [Abstract][Full Text] [Related]
5. Use of sodium-glucose cotransporter type 2 inhibitors in older adults with type 2 diabetes mellitus.
Mikhail N
South Med J; 2015 Feb; 108(2):91-6. PubMed ID: 25688893
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of dapagliflozin as monotherapy in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.
Feng M; Lv H; Xu X; Wang J; Lyu W; Fu S
Medicine (Baltimore); 2019 Jul; 98(30):e16575. PubMed ID: 31348290
[TBL] [Abstract][Full Text] [Related]
7. A consensus statement for the clinical use of the renal sodium-glucose co-transporter-2 inhibitor dapagliflozin in patients with type 2 diabetes mellitus.
Avogaro A; Giaccari A; Fioretto P; Genovese S; Purrello F; Giorgino F; Del Prato S
Expert Rev Clin Pharmacol; 2017 Jul; 10(7):763-772. PubMed ID: 28431476
[TBL] [Abstract][Full Text] [Related]
8. Dapagliflozin, an SGLT2 inhibitor for the treatment of type 2 diabetes.
Demaris KM; White JR
Drugs Today (Barc); 2013 May; 49(5):289-301. PubMed ID: 23724409
[TBL] [Abstract][Full Text] [Related]
9. [Dapagliflozin, the first SGLT-2 inhibitor in the treatment of type 2 diabetes].
Albarrán OG; Ampudia-Blasco FJ
Med Clin (Barc); 2013 Sep; 141 Suppl 2():36-43. PubMed ID: 24444523
[TBL] [Abstract][Full Text] [Related]
10. Dapagliflozin for the treatment of type 2 diabetes.
Brooks AM; Thacker SM
Ann Pharmacother; 2009 Jul; 43(7):1286-93. PubMed ID: 19584379
[TBL] [Abstract][Full Text] [Related]
11. Update review of the safety of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with type 2 diabetes mellitus.
Carlson CJ; Santamarina ML
Expert Opin Drug Saf; 2016 Oct; 15(10):1401-12. PubMed ID: 27449721
[TBL] [Abstract][Full Text] [Related]
12. The clinical efficacy and safety of sodium glucose cotransporter-2 inhibitors in adults with type 2 diabetes mellitus.
Riser Taylor S; Harris KB
Pharmacotherapy; 2013 Sep; 33(9):984-99. PubMed ID: 23744749
[TBL] [Abstract][Full Text] [Related]
13. Dapagliflozin, an oral sodium glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus.
Calado J
IDrugs; 2009 Dec; 12(12):785-98. PubMed ID: 19943222
[TBL] [Abstract][Full Text] [Related]
14. Dapagliflozin-Associated Diabetic Ketoacidosis.
Chakinala RC; Chang AP; Solanki S; Haq KF; Cho R
Am J Ther; 2018; 25(6):e765-e766. PubMed ID: 29672334
[No Abstract] [Full Text] [Related]
15. Cost-Effectiveness of Dapagliflozin as Add-On to Metformin for the Treatment of Type 2 Diabetes Mellitus in Greece.
Tzanetakos C; Tentolouris N; Kourlaba G; Maniadakis N
Clin Drug Investig; 2016 Aug; 36(8):649-59. PubMed ID: 27221806
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
Scheen AJ
Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697
[TBL] [Abstract][Full Text] [Related]
17. Dapagliflozin (Farxiga) - a new indication for heart failure.
Med Lett Drugs Ther; 2020 Jun; 62(1601):102-103. PubMed ID: 32724023
[No Abstract] [Full Text] [Related]
18. Targeting renal glucose reabsorption for the treatment of type 2 diabetes mellitus using the SGLT2 inhibitor dapagliflozin.
Jabbour SA; Whaley JM; Tirmenstein M; Poucher SM; Reilly TP; Boulton DW; Saye J; List JF; Parikh S
Postgrad Med; 2012 Jul; 124(4):62-73. PubMed ID: 22913895
[TBL] [Abstract][Full Text] [Related]
19. A Review of Sodium Glucose Co-transporter 2 Inhibitors Canagliflozin, Dapagliflozin and Empagliflozin.
Syed SH; Gosavi S; Shami W; Bustamante M; Farah Z; Teleb M; Abbas A; Said S; Mukherjee D
Cardiovasc Hematol Agents Med Chem; 2015; 13(2):105-12. PubMed ID: 26549321
[TBL] [Abstract][Full Text] [Related]
20. [Dapagliflozin: Beyond glycemic control in the treatment of type 2 diabetes mellitus].
Sanz-Serra P; Pedro-Botet J; Flores-Le Roux JA; Benaiges D; Chillarón JJ
Clin Investig Arterioscler; 2015; 27(4):205-11. PubMed ID: 25648671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
